Welcome to our dedicated page for Veeva Systems news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Systems stock.
Veeva Systems Inc. (NYSE: VEEV) is a global leader in cloud-based software solutions specifically tailored for the life sciences industry. Headquartered in the San Francisco Bay Area, Veeva Systems provides innovative technology that helps pharmaceutical and biotech companies streamline their operations, ensure compliance, and bring products to market faster. Veeva's product offerings address key operational and regulatory needs, ranging from customer relationship management (CRM) to content management and data analytics.
Two of the company's flagship products include Veeva CRM and Veeva Vault. Veeva CRM is designed for companies with a salesforce, providing tools to manage customer interactions more efficiently. Meanwhile, Veeva Vault is a versatile content management platform that supports various functions such as clinical trials, regulatory submissions, and quality management within life sciences companies.
Veeva serves a diverse customer base, ranging from emerging biotechs to some of the world's largest pharmaceutical companies. Its commitment to product excellence, customer success, and continuous innovation is evident as Veeva frequently updates its offerings to meet the evolving needs of the industry. Recently, Veeva announced that Boehringer Ingelheim has selected Veeva Vault Clinical and Veeva Vault RIM applications to streamline clinical execution and improve regulatory management in its animal health business unit.
Another notable achievement for Veeva was the launch of the Veeva AI Partner Program, designed to help partners integrate Generative AI solutions seamlessly with Veeva Vault applications. This initiative highlights Veeva's ongoing efforts to leverage advanced technologies to enhance its product ecosystem. Furthermore, the introduction of Veeva Vault CRM Campaign Manager aims to simplify and speed up non-personal promotion to healthcare professionals, ensuring consistent and compliant marketing efforts.
Financially, Veeva Systems has shown strong performance with its fiscal year 2024 results reflecting robust growth. The company continues to invest in its innovation engine and strategic partnerships, setting the stage for sustained, profitable growth. Veeva's recent financial outlook for fiscal year 2025 and first quarter results for 2024 further underline its market leadership and operational excellence.
For more information about Veeva Systems, its products, and latest updates, visit www.veeva.com.
Veeva Systems reported strong financial results for the fourth quarter and fiscal year ending January 31, 2022. Total revenues for Q4 reached $485.5 million, a 22% increase year-over-year. Subscription services revenues grew by 23% to $395.7 million. Operating income rose 21% to $119.7 million, while non-GAAP net income increased 17% to $147.0 million. For fiscal 2022, revenues totaled $1,850.8 million, a 26% increase, with net income up 12% to $427.4 million. The company provided guidance for fiscal Q1 2023 with total revenues expected between $494 million and $496 million.
Veeva Systems (NYSE: VEEV) announced the inaugural Veeva TMF Innovation Forum to be held online on March 10, 2022. The event will gather over 250 experts in trial master file (TMF) management to discuss advancements in digital clinical trials. Key themes include the role of TMF as a strategic asset, leveraging artificial intelligence for process automation, optimizing outsourcing models, and meeting new regulatory requirements. The forum aims to enhance clinical strategy and enable a connected clinical ecosystem.
Veeva Systems announced that Idorsia Pharmaceuticals has expanded its use of the Veeva Vault Clinical Suite to include Vault CDMS for electronic data capture (EDC) and coding. This collaboration allows Idorsia to speed up its clinical trials by utilizing a modern data management system to enhance study execution and management. The cloud-based Vault CDMS will enable Idorsia's clinical teams to independently build studies and make mid-study amendments efficiently, streamlining trial content and data management.
Veeva Systems reports significant adoption of its Vault PromoMats platform by over 300 emerging and mid-size biopharmaceutical companies globally, with more than 40 new clients in the U.S. in the past year. This software aids in streamlining medical, legal, and regulatory review processes and managing digital assets efficiently. The service is designed to support the growing demand for rapid content generation crucial for healthcare professionals. Industry leaders express satisfaction with the platform's capability to enhance compliance, visibility, and efficiency during product launches.
Veeva Systems will announce its financial results for the fourth quarter and full fiscal year ending January 31, 2022, on March 2, 2022, after market close. A conference call will be held that day at 2:00 PM PT to discuss these results. Prepared remarks will be available on the investor relations website at 1:05 PM PT. Veeva is recognized as a leader in cloud software for the life sciences industry, serving over 1,000 customers including major pharmaceutical companies.
Veeva Systems (NYSE: VEEV) announced the appointment of four new board members: Tim Cabral, Priscilla Hung, Tina Hunt, and Marshall Mohr, effective January 21, 2022. These individuals bring extensive experience in life sciences and enterprise software. Cabral, former CFO of Veeva, is now involved with ServiceTitan and Doximity. Hung leads operations at Guidewire Software, Hunt is an executive at IDEXX, and Mohr previously managed global business services at Intuitive. Ron Codd will retire from the board in June 2022 after a decade of service.
Veeva Systems announced that the Lymphoma Academic Research Organization (LYSARC) has chosen the Veeva Development Cloud to boost operational efficiency in lymphoma therapy research. LYSARC aims to integrate applications from Vault Clinical, Vault Quality, and Vault Safety into a cohesive platform for enhanced trial execution and data quality. This partnership will facilitate greater scalability and speed in developing innovative lymphoma treatments, impacting over 750 patients annually across regions including Belgium, France, and Portugal.
On December 14, 2021, Veeva Systems (NYSE: VEEV) announced PharmaEssentia's adoption of Veeva Data Cloud to aid in the launch of BESREMi, a novel therapy for polycythemia vera (PV). The platform will provide critical patient insights for targeting healthcare providers and analyzing patient journeys. PharmaEssentia's U.S. General Manager highlighted the platform's role in enhancing visibility of patient data, while Veeva's CEO emphasized its support for various analytics and workflow operations. The collaboration aims to improve HCP education about the new treatment.
Veeva Systems (NYSE: VEEV) has acquired Veracity Logic, a cloud software provider for randomization and trial supply management (RTSM). This acquisition aims to enhance Veeva's capabilities in streamlining complex clinical trial processes. The Veeva RTSM solution has already supported 175 trials across 60 countries. The integration will be managed by Veracity's founder, Steve Zimmerman, alongside key executives. Veeva emphasizes customer choice in integrating RTSM with various systems while maintaining existing partnerships. The forward-looking statements warn of the inherent risks in acquisitions.
FAQ
What is the current stock price of Veeva Systems (VEEV)?
What is the market cap of Veeva Systems (VEEV)?
What does Veeva Systems Inc. do?
Where is Veeva Systems Inc. headquartered?
What are Veeva's main products?
Who are Veeva Systems' customers?
What recent partnerships has Veeva announced?
What is the Veeva AI Partner Program?
How has Veeva performed financially recently?
What is Veeva Vault CRM Campaign Manager?
What industry does Veeva Systems primarily serve?
How does Veeva contribute to the life sciences industry?
